Signal Genetics Announces Master Service Agreement

Go back to Signal Genetics Announces Master Service Agreement

Signal Genetics (SGNL) Enters MSA with Leading Pharmaceutical Company

June 30, 2015 8:32 AM EDT

Signal Genetics (Nasdaq: SGNL) announced the signing of a Master Service Agreement (MSA) with a leading pharmaceutical company. Under the MSA, Signal's proprietary MyPRS® genetic test will be run across multiple clinical trials in connection with the development of novel treatments for patients with... More